Characterization of absorbable collagen sponges as recombinant human bone morphogenetic protein-2 carriers

被引:42
|
作者
Friess, W
Uludag, H
Foskett, S
Biron, R
Sargeant, C
机构
[1] Univ Erlangen Nurnberg, Dept Pharmaceut Technol, D-91058 Erlangen, Germany
[2] Univ Alberta, Dept Biomed Engn, Edmonton, AB T6G 2G3, Canada
[3] Genet Inst Inc, Andover, MA 01810 USA
关键词
collagen; bone morphogenetic protein; sterilization; crosslinking;
D O I
10.1016/S0378-5173(99)00128-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
For clinical use recombinant human bone morphogenetic protein-2 (rhBMP-2) is soaked onto an absorbable collagen sponge (ACS) for bone regeneration. Therefore, loss of rhBMP-2 upon mechanical handling during implantation and a potential effect of the carrier on in vivo retention is of interest. The interactions between drug and carrier were looked at from the application mode and the amount of protein which can be mechanically expressed from the combination was investigated. The results indicated that rhBMP-2 binds to the collagen system. The most hydrophilic double extended homodimer showed the least binding affinity to ACS. By extending the waiting time between soaking and implantation, protein incorporation could be increased. In addition, the amount of rhBMP-2 which could be expressed was reduced by heavier ACS material and allowed for a shorter waiting period, especially at lower rhBMP-2 concentration. Crosslinking of ACS with formaldehyde led to reduced binding of rhBMP-2 to collagen either by direct hindrance of binding or reduction in swelling and number of binding sites available. Higher product pH or anion concentration enabled to increase rhBMP-2 incorporation but was limited by the potential precipitation of rhBMP-2. Despite a variety of chemical changes of ACS by ethylene oxide sterilization incorporation was not changed significantly. The in vivo release kinetics of I-125-rhBMP-2 from the collagen sponge were studied using a rat ectopic implant model. The ACS/rhBMP-2 systems tested demonstrated small but significant differences in the in vivo retention of rhBMP-2. Consequently, it is important to have as little variability in pH, anion concentration, crosslinking, and ACS mass as possible to achieve consistent or maximum binding and to avoid rhBMP-2 precipitation. Furthermore, these characteristics can be important for other in vivo applications. (C) 1999 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:51 / 60
页数:10
相关论文
共 50 条
  • [21] Peptide Hydrogel for Sustained Release of Recombinant Human Bone Morphogenetic Protein-2 In Vitro
    Wang, Dalin
    Qi, Guangyan
    Zhang, Mingcai
    Carlson, Brandon
    Gernon, Matthew
    Burton, Douglas
    Sun, Xiuzhi Susan
    Wang, Jinxi
    JOURNAL OF FUNCTIONAL BIOMATERIALS, 2024, 15 (12)
  • [22] Quality-of-Life Outcomes following Thoracolumbar and Lumbar Fusion with and without the Use of Recombinant Human Bone Morphogenetic Protein-2: Does Recombinant Human Bone Morphogenetic Protein-2 Make a Difference?
    Lubelski, Daniel
    Alvin, Matthew D.
    Torre-Healy, Andrew
    Abdullah, Kalil G.
    Nowacki, Amy S.
    Whitmore, Robert G.
    Steinmetz, Michael P.
    Benzel, Edward C.
    Mroz, Thomas E.
    GLOBAL SPINE JOURNAL, 2014, 4 (04) : 245 - 254
  • [23] Safety of recombinant human bone morphogenetic protein-2 after spinal laminectomy in the dog
    Meyer, RA
    Gruber, HE
    Howard, BA
    Tabor, OB
    Murakami, T
    Kwiatkowski, TC
    Wozney, JM
    Hanley, EN
    SPINE, 1999, 24 (08) : 747 - 754
  • [24] Effect of FK506 on osteoinduction by recombinant human bone morphogenetic protein-2
    Kaihara, S
    Bessho, K
    Okubo, Y
    Sonobe, J
    Kusumoto, K
    Ogawa, Y
    Iizuka, T
    LIFE SCIENCES, 2002, 72 (03) : 247 - 256
  • [25] Effect of aging on the osteoinductive activity of recombinant human bone morphogenetic protein-2 in rats
    Hara, Tomoya
    Kakudo, Natsuko
    Morimoto, Naoki
    Horio, Osamu
    Ogura, Tsunetaka
    Kusumoto, Kenji
    JOURNAL OF SURGICAL RESEARCH, 2015, 195 (01) : 377 - 383
  • [26] Safety of recombinant human bone morphogenetic protein-2 after spinal laminectomy in the dog
    Meyer, RA
    Gruber, HE
    Howard, BA
    Tabor, OB
    Murakami, T
    Kwiatkowski, TC
    Wozney, JM
    Hanley, EN
    SPINE, 2000, 25 (06) : 115S - 122S
  • [27] Experimental spinal fusion using sintered bovine bone coated with type I collagen and recombinant human bone morphogenetic protein-2
    Minamide, A
    Tamaki, T
    Kawakami, M
    Hashizume, H
    Yoshida, M
    Sakata, R
    SPINE, 1999, 24 (18) : 1863 - 1870
  • [28] Comparison between heparin-conjugated fibrin and collagen sponge as bone morphogenetic protein-2 carriers for bone regeneration
    Yang, Hee Seok
    La, Wan-Geun
    Cho, Yong-Min
    Shin, Wangsoo
    Yeo, Guw-Dong
    Kim, Byung-Soo
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2012, 44 (05) : 350 - 355
  • [29] Effect of recombinant irisin on recombinant human bone morphogenetic protein-2 induced osteogenesis and osteoblast differentiation
    Ohyama, Yohei
    Ohta, Yoichi
    Sugama, Ryo
    Minoda, Yukihide
    Masuda, Sho
    Terai, Hidetomi
    Nakamura, Hiroaki
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2024, 734
  • [30] Effective doses of recombinant human bone morphogenetic protein-2 in experimental spinal fusion
    Sandhu, HS
    Kanim, LEA
    Kabo, JM
    Toth, JM
    Zeegen, EN
    Liu, D
    Delamarter, RB
    Dawson, EG
    SPINE, 1996, 21 (18) : 2115 - 2122